人羊水间充质干细胞治疗肿瘤的临床研究进展

人羊水间充质干细胞(Human amniotic fluid derived mesenchymal stem cells,AF-MSCs)是一类具有高度增殖、自我更新和多项分化潜能的干细胞,即使经过多次传代其生物学特性也不会发生改变。有研究表明,AF-MSCs具有免疫原性低、不成瘤性和肿瘤细胞亲嗜性等特点,而且能够迁移到肿瘤病灶。因此,AF-MSCs作为转运载体介导药物靶向治疗肿瘤具有潜在的优势。同时,通过羊膜腔穿刺获得羊水有利于避免胚胎干细胞研究有关的伦理问题,可作为一种理想的治疗方法。本文通过回顾、总结人羊水间充质干细胞的研究进展,展望人羊水间充质干细胞治疗肿瘤的应用前景。

Research Progess of Human Amniotic Fluid Derived Mesenchymal Stem Cells in Tumors

Human amniotic fluid derived mesenchymal stemcells (AF-MSCs) is a kind of highly proliferation with the biological characteristics of self-renewal and multiple differentiation potential of stem cells and never change by passaging. Researches have shown that the AF-MSCs also has the features of low immunogenicity, non formation, tumor cell dear tropism, and migrates to tumor cells. Thus, AF-MSCs could be used as a transporter mediated drug therapy of tumor with potential advantages. What'' more, amniotic fluid can be obtained by amniocentesis that could avoid the ethical issues related to embryonic stemcells. This paper reviewed and summarized the research progress on human amniotic fluid derived mesenchymal stemcells, and prospected the clinical application of tumor treatment.